Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trinity Biotech ( (TRIB) ) has shared an announcement.
On March 10, 2026, Trinity Biotech issued a trading and business update indicating it expects fourth-quarter 2025 revenue of approximately $11.5 million to $12.5 million, down from $15.9 million a year earlier, mainly due to global HIV testing market disruption and manufacturing transition effects. The company has secured a waiver and covenant deferral on its credit agreement through July 1, 2026, obtained key regulatory approval in February 2026 to offshore Uni-Gold HIV production, is accelerating its outsourcing-driven Comprehensive Transformation Plan, and is sharpening its commercial push in rapid HIV and diabetes diagnostics while advancing its CGM+, EpiCapture and PrePsia pipeline, moves aimed at improving long-term profitability despite near-term revenue volatility.
The most recent analyst rating on (TRIB) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
Overall score is held down primarily by weak financial performance (sharp TTM revenue decline, deep losses, negative equity, and negative free cash flow). Technicals are only mildly supportive with mixed trend signals, and valuation provides limited support due to a negative P/E and no dividend yield data.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech plc is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. It develops, acquires, manufactures and markets diagnostic systems for point-of-care and clinical laboratory markets, with key product franchises in rapid HIV testing and HbA1c-based diabetes care.
Average Trading Volume: 3,368,643
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.06M
Find detailed analytics on TRIB stock on TipRanks’ Stock Analysis page.